Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combination therapy for the treatment of cancer

A composition and inhibitor technology, applied in the field of combined anticancer therapy and/or prevention, can solve the problems of no cancer, toxic side effects of cancer treatment, inability to distinguish normal cells from malignant cells, etc.

Inactive Publication Date: 2014-11-12
TILTAN PHARMA LTD
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] A problem with the use of cytotoxic agents that act by disrupting cell division is that they cannot distinguish between normal and malignant cells: any dividing cell is a potential target for their action
As a result, cell populations that normally exhibit high levels of proliferation, such as the bone marrow, are affected, leading to toxic side effects commonly associated with cancer therapy
[0007] With few exceptions, no single drug or combination of drugs cures most cancers

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination therapy for the treatment of cancer
  • Combination therapy for the treatment of cancer
  • Combination therapy for the treatment of cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0097] during the test

[0098] The entire study lasted 18 days (duration of treatment: 14 days, ie a two-week treatment regimen). Tumor cell inoculation was diary as "Day 1". Compositions were administered intraperitoneally (IP) six days a week starting on day 4.

[0099] Tumor cells: mouse pancreatic-adenocarcinoma cell line PANC02 (a gift from Dr. A. Marten, University of Heidelberg, Germany).

[0100] test animals

[0101] CB6F1 female mice with an average body weight of 21.1 g, 10 mice per treatment group.

[0102] Treatment Groups and Compositions

[0103] Five test groups were conducted, each group administered a different therapeutic composition and the protocol is detailed in Tables 1 and 2 below.

[0104] Treatment groups were administered vehicle alone (Group 1), the combination of TL-118 and gemcitabine (Groups 2 and 3), gemcitabine alone (Group 4), and TL-118 alone (Group 5).

[0105] TL-118 refers to the combination therapy as detailed in Table 2 below.

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a combination comprising: a composition comprising at least one non-steroidal anti-inflammatory agent and at least one cytotoxic agent; and a composition comprising at least one ribonucleotide reductase inhibitor. The invention further includes kits comprising a combination of the invention and methods and uses of a combination of the invention for the treatment of cancer treatment of cancer, including solid tumors or tumor metastasis.

Description

technical field [0001] The present invention relates to the field of combined anticancer therapy and / or prevention. Background technique [0002] Cancer generally refers to one of a group of diseases caused by the uncontrolled abnormal growth of cells that can spread to nearby tissues or other parts of the body. Cancer cells can form solid tumors, in which cancer cells are clustered together, or exist as scattered cells, as in leukemia. Normal cells divide until they reach maturity and then only as necessary to replace damaged or dead cells. Often, cancer cells are called "malignant" because they divide endlessly, eventually squeezing out of surrounding tissue and spreading to other parts of the body. The tendency of cancer cells to invade and spread from one organ to another or from one part of the body to another distinguishes them from benign tumor cells, which grow excessively but do not spread to other organs or parts of the body. Malignant cancer cells eventually me...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K45/06A61K31/196A61K31/675A61K31/7068
CPCA61K31/7068A61K31/675A61K31/4164A61K31/655A61K31/122A61K31/429A61K45/06A61K31/196A61P29/00A61P35/00A61P35/02A61P35/04A61P43/00A61K2300/00
Inventor 达夫娜·费特尔伯格兹维亚·贝尔克曼什姆埃尔·本-萨松丹·格多斯托布
Owner TILTAN PHARMA LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com